Vlad Bystricky

could you just talk more about how you're thinking about the potential for a more positive inflection within life sciences in HST over the coming quarters

can you just talk about what price cost was in the quarter, how you see it evolving going forward through the year

can you just talk about how much price ended up contributing to top line overall in 'twenty five

how should we think about the potential for incremental know, meaningful portfolio pruning

could you give any color on what price actually contributed in 3Q and how you're thinking about pricing heading into '26

help me understand a little better kind of the cadence between 3Q and 4Q

can you just give us a little more granularity or specificity on what's embedded now in the current guidance

I think you called out positive ag orders growth in the quarter, but there's also still a red line next to ag on the slide

have you seen any evidence from your customers of them pulling forward any order activity, if you will

whether you see that opportunity as something that could be repeatable and meaningful for other customers

Have you made any specific assumptions relative to potential tariff impacts coming in

the mix of proprietary versus competitive targets in that $10 billion plus potential funnel